資源描述:
《舌下免疫治療常年性變應(yīng)性鼻炎臨床研究》由會(huì)員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、舌下免疫治療常年性變應(yīng)性鼻炎臨床研究作者單位:525011廣東省茂名石化醫(yī)院通訊作者:梁芳健【摘要】口的觀察標(biāo)準(zhǔn)化粉塵蛾變應(yīng)原疫苗舌下含服免疫治療常年性變應(yīng)性鼻炎的臨床療效及安全性。方法82例均対粉塵喊過(guò)敏的常年性變應(yīng)性鼻炎患者,給予標(biāo)準(zhǔn)化粉塵喊變應(yīng)原疫苗舌下含服免疫治療1年,觀察免疫治療過(guò)程屮局部及全身不良反應(yīng)發(fā)生情況,并通過(guò)臨床癥狀評(píng)分及鼻結(jié)膜炎札I關(guān)生活質(zhì)量問(wèn)卷進(jìn)行評(píng)價(jià)其療效。結(jié)果局部不良反M有5例(6.1%),表現(xiàn)為口腔局部瘙癢不適;全身不良反應(yīng)冇10例(12.2%),包括胃腸道反應(yīng)、尋麻疹、鼻炎癥狀加重等,主要發(fā)生丁?劑量遞增階段,均為輕至中度反應(yīng),未發(fā)生過(guò)敏性休克
2、等嚴(yán)重不良反應(yīng)。臨床癥狀及生活質(zhì)量均得到顯著性改善(P〈0.01),治療總冇效率為84.1%(69/82)o結(jié)論舌下含服途徑進(jìn)行特異性免疫治療常年性變應(yīng)性鼻炎具有良好的臨床療效及安全性,值得推廣應(yīng)用。【關(guān)鍵詞】鼻炎;變應(yīng)性;常年性;脫敏;免疫性ClinicalstudyofperennialallergicrhinitiswithsublingualimmunotherapyLTANGFang-jian.MaomingShihuaHospital,Maoming525011,China[Abstract]ObjectiveToobservetheefficacyandsafe
3、tyofsublingualiinmunotherapyintreatingperennialallergicrhinitis.Methods82patientswithperennialallergicrhinitiscausedbyDermatophagoidesfarinacwerecnrolledinthisself-contraststudy.Clinicalefficacywasevaluatedbysymptomscoresvisualanaloguesealeandrhinoconjunctivitisqualityoflifequestiormaireaft
4、eroneyearofsublingualimmunotherapyandcomparedwithpre-treatmentscores.ResultsOralitchingassociatedwithdropintakewasreportedby5subjects(6.1%)inthesublingualimmunotherapy.Therewerealso10patients(12.2%)whoexpericnccdsystemicreactionsinthesublingualimmunotherapy,includinggastrointestinalsymptoms
5、,urticaria,andrhinitisexacerbations.Systemicreactionsweremainlyobservedinpatientsduringtheup-dosingphaseoftreatment.Thereweremildormoderateandnoanaphylacticshockoccurred?Aftertherapyforoneyear,clinicalsymptomsandqualityoflifeweresignificant/lyimproved(P<0.01).Therewereeffectiveaftertreatmen
6、tin84.1%cases(69/82).ConclusionSublingualimmunotherapywithdermatophagoidesfarinaesufferingfromperennialal1ergicrhinitis,soitwasworthspreading.[Keywords]Rhinitis;Allergic;Perennial;Desensitization;Immunologic常年性變應(yīng)性鼻炎的患病率呈上升趨勢(shì),已成為全球性健康問(wèn)題[1],我國(guó)中心城市變應(yīng)性鼻炎的自報(bào)患者率達(dá)8%?20%,是嚴(yán)重影響我國(guó)人口健康的常見(jiàn)疾病
7、〈sup>[2]o常年性變應(yīng)性鼻炎除導(dǎo)致鼻塞、流涕、?鼻癢、噴嚏以及眼癢、流淚等典型癥狀外,還可影響患者的生活質(zhì)量,誘發(fā)支氣管哮喘等[3]oH治療主要包括避免接觸變應(yīng)原、藥物治療、免疫治療及宣傳教育[1],變應(yīng)原特異性免疫療法是目前惟一可能影響疾病口然進(jìn)程的對(duì)因治療措施[1,4,5]o傳統(tǒng)免疫療法是經(jīng)皮下注射途徑給約,以遞增劑量的方法給予患者變應(yīng)原疫苗,從而改善暴銘于該變應(yīng)原時(shí)產(chǎn)牛的臨床癥狀,且證實(shí)對(duì)常年性變應(yīng)性鼻炎有確切療效